                         SEQUENCE LISTING

<110>  BicycleTx Limited
 
<120>  HETEROTANDEM BICYCLIC PEPTIDE COMPLEXES

<130>  BIC-C-P2972PCT

<150>  US 63/135,273
<151>  2021-01-08

<150>  US 63/262,599
<151>  2021-10-15

<160>  14    

<170>  PatentIn version 3.5

<210>  1
<211>  15
<212>  PRT
<213>  Artificial

<220>
<223>  Synthetic Peptide


<220>
<221>  Xaa
<222>  (3)..(3)
<223>  Xaa is 1Nal

<220>
<221>  Xaa
<222>  (7)..(7)
<223>  Xaa is HArg

<220>
<221>  Xaa
<222>  (13)..(13)
<223>  Xaa is HyP

<400>  1

Cys Pro Xaa Asp Cys Met Xaa Asp Trp Ser Thr Pro Xaa Trp Cys 
1               5                   10                  15  


<210>  2
<211>  15
<212>  PRT
<213>  Artificial

<220>
<223>  Synthetic Peptide


<220>
<221>  Xaa
<222>  (2)..(2)
<223>  Xaa is HyP

<220>
<221>  Xaa
<222>  (14)..(14)
<223>  Xaa is HArg

<400>  2

Cys Xaa Leu Val Asn Pro Leu Cys Leu His Pro Asp Trp Xaa Cys 
1               5                   10                  15  


<210>  3
<211>  15
<212>  PRT
<213>  Artificial

<220>
<223>  Synthetic Peptide

<400>  3

Cys Ser Ala Gly Trp Leu Thr Met Cys Gln Lys Leu His Leu Cys 
1               5                   10                  15  


<210>  4
<211>  13
<212>  PRT
<213>  Artificial

<220>
<223>  Synthetic Peptide


<220>
<221>  Xaa
<222>  (3)..(3)
<223>  Xaa is HArg

<220>
<221>  Xaa
<222>  (7)..(7)
<223>  Xaa is tBuAla

<220>
<221>  Xaa
<222>  (11)..(11)
<223>  Xaa is HArg

<400>  4

Cys Val Xaa Glu Cys Ala Xaa Leu Phe Pro Xaa Thr Cys 
1               5                   10              


<210>  5
<211>  13
<212>  PRT
<213>  Artificial

<220>
<223>  Synthetic Peptide


<220>
<221>  Xaa
<222>  (3)..(3)
<223>  Xaa is Cba

<400>  5

Cys Tyr Xaa Pro Asp Tyr Leu Cys Ala Asp Glu Tyr Cys 
1               5                   10              


<210>  6
<211>  13
<212>  PRT
<213>  Artificial

<220>
<223>  Synthetic Peptide

<400>  6

Cys Tyr Leu Pro Asp Tyr Leu Cys Gly Asp Glu Tyr Cys 
1               5                   10              


<210>  7
<211>  13
<212>  PRT
<213>  Artificial

<220>
<223>  Synthetic Peptide

<400>  7

Cys Asp Leu Thr Thr His Asn Cys Gln Trp Gly Ile Cys 
1               5                   10              


<210>  8
<211>  14
<212>  PRT
<213>  Artificial

<220>
<223>  Synthetic Peptide

<400>  8

Cys Asn Leu Gln Ala Pro Cys Met Gln Thr Gly Lys Val Cys 
1               5                   10                  


<210>  9
<211>  12
<212>  PRT
<213>  Artificial

<220>
<223>  Synthetic Peptide

<400>  9

Cys Asn Leu Gln Asn Pro Cys Met Lys Phe Pro Cys 
1               5                   10          


<210>  10
<211>  13
<212>  PRT
<213>  Artificial

<220>
<223>  Synthetic Peptide


<220>
<221>  Xaa
<222>  (9)..(9)
<223>  Xaa is dK(PYA)

<400>  10

Cys Tyr Leu Pro Asp Tyr Leu Cys Xaa Asp Glu Tyr Cys 
1               5                   10              


<210>  11
<211>  15
<212>  PRT
<213>  Artificial

<220>
<223>  Synthetic Peptide

<400>  11

Cys Leu Leu His Asp His Cys Pro Asn Thr His Pro Lys Leu Cys 
1               5                   10                  15  


<210>  12
<211>  14
<212>  PRT
<213>  Artificial

<220>
<223>  Synthetic Peptide

<400>  12

Cys Val Gly Leu Glu Glu Leu Gly Pro Cys Ser Asp Leu Cys 
1               5                   10                  


<210>  13
<211>  13
<212>  PRT
<213>  Artificial

<220>
<223>  Synthetic Peptide

<400>  13

Cys Arg Trp His Phe Ser Glu Pro Cys Gly Ala Trp Cys 
1               5                   10              


<210>  14
<211>  13
<212>  PRT
<213>  Artificial

<220>
<223>  Synthetic Peptide

<400>  14

Cys Arg Trp Ser Val Glu Asp Pro Cys Gly Ala Trp Cys 
1               5                   10              


